Introduction
Introduction

By virtue of its antiplatelet action, sarpogrelate (SAR), a serotonin antagonist (5-HT2A receptor antagonist), is indicated for the therapy of peripheral vascular disease [1, 2]. Not only does this agent inhibit 5-HT induced increase in intracellular Ca
2+ [Ca 2+ ]i and cell proliferation in vascular smooth muscle cells [3, 4] , it has also been reported to produce similar effects in the coronary artery smooth muscle cells [5] . Furthermore, SAR has been shown to attenuate arrhythmias and heart dysfunction due to acute myocardial infarction (MI) in rats [6] and improve the recovery of cardiac performance in ischaemic reperfused hearts by reducing changes in the high energy phosphate stores and myocardial ultrastructure [7] . Since prolonged activation of 5-HT2A receptors and associated signal transduction mechanisms have been observed to produce cardiac hypertrophy and congestive heart failure (CHF) [8] , it is possible that SAR may exert some beneficial effects in CHF by attenuating changes in cardiac performance. This study was therefore undertaken to determine if the animals with CHF showed improvement in heart function upon treatment with SAR. In view of the critical role played by subcellular remodelling in the development of CHF [9, 10] [11] , which has similar properties as SAR in producing antiplatelet effects and vasodilation [11] , was used in this study for the purpose of comparison. It should be mentioned that both SAR and CIL are novel antiplatelet agents, which exert vasodilatory effects and are used for the treatment of complications associated with peripheral thromboembolism as well as prevention of coronary restenosis [1, 2, [11] [12] [13] . [14] [15] [16] . Briefly, the heart in anaesthetized animals was exposed and the left coronary artery was ligated at about 2 mm from its origin at the aorta. [1, 6, 11] .
, alterations in biochemical activities and molecular composition of sarcoplasmic reticulum (SR) and myofibrils in the failing heart were examined with or without SAR treatment. To test if other antiplatelet agents exert beneficial effects similar to those for SAR in CHF, cilostazol (CIL), a phosphodiesterase-III (PDE-III) inhibitor
Materials and methods
Experimental model and study design
All experimental protocols were approved by the Animal Care Committee of the University of Manitoba following guidelines established by the Canadian Institutes of Health Research. These guidelines conform to the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (NIH Publication No. 85-23, revised 1996). MI was induced in male Sprague-Dawley rats (175-200 g) by occlusion of the left coronary artery as described earlier
Haemodynamic studies
Haemodynamic measurements were carried out at 8 weeks after surgery as described previously [14] [15] [16] 
Analysis of cardiac myosin heavy chain isoforms
Cardiac MHC isoforms were determined under denaturing conditions; both ␣-and ␤-MHCs were separated on a 4% polyacrylamide gel upon loading 4g protein/well as described previously [14, 18] Determination of SR Ca 2+ -uptake and -release activities SR vesicles were isolated as described previously [15, 19] 
Northern blot analysis
Total RNA was isolated from the viable LV of sham control and infarcted rats with or without drug treatment by the acid guanidinium thiocyanatephenol-chloroform method [15, 16, 18, 19] Figure 2 and Figure 3A 
Results
General characteristics and mortality
Myofibrillar ATPase activities and myosin heavy chain isoforms
The data in Figure 5 show (Fig. 6B) and that for ␣-MHC mRNA was increased by 88% (Fig. 6C) Figure 3B [17] as well as in acute MI in rats [6] . [23, 24] . [32] . SAR and CIL treatment also improved SR regulation by recovering PLB phosphorylation, which was decreased in the failing hearts and contributed towards the inhibition of SERCA2a function. Of the several protein kinases, which mediate the phosphorylation of PLB, the cAMP-dependent protein kinase A (PKA) appears to be an important mediator of the enhanced cardiac contractility [33] . It should also be pointed out that in agreement with previous studies [34, 35] 
in LV of the infarcted rats. Therapy with SAR and CIL significantly attenuated the increase in ␤-MHC as well as the decrease in ␣-MHC due to MI at both protein and mRNA levels (Fig. 6). In order to show if the phosphorylation of cTnI is altered in the experimental animals, protein content for both unphosphorylated and phosphorylated forms of cTnI were determined. The data in
Discussion
In the present study, we showed for the first time that antiplatelet agents, SAR and CIL, attenuated remodelling of subcellular
Antiplatelet agents attenuate structural ventricular remodelling and improve cardiac function
SAR has been shown to improve cardiac function and LV pressures in ischaemia/reperfusion injury in isolated hearts
Modulation of SR remodelling by antiplatelet agents in CHF
Fig. 3 Representative western blots and densitometric analysis of protein contents for sarcoplasmic reticulum phosphorylated PLB (A) and phosphorylated cTnI (B) in sham, vehicle-treated (MI), sarpogrelatetreated (MI+SAR) and cilostazol-treated (MI+CIL) rats
Modulation of myofibrillar remodelling by antiplatelet agents in CHF
Consistent with our previous observations [14, 18] 
SAR and CIL as antiplatelet agents in CHF
Recently Nebigil et al. [8] [40, 41] . Although this is a first study which has shown antihypertrophic effect of CIL, other PDE-III inhibitors, such as amrinone and milrinone have been reported to reduce cardiac hypertrophy in the failing heart [42, 43, 44] [45] . On the other hand, cardiac hypertrophy over a prolonged period is known to exert deleterious action on heart function as a consequence of subcellular remodelling under different pathophysiological conditions [9, 10] 
